Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-10-29
2010-02-16
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S001690
Reexamination Certificate
active
07662775
ABSTRACT:
The invention relates to a convenient screening tool for identifying an agent for treating diabetes. The screening tool is a G protein-coupled receptor, a variant of the G protein-coupled receptor, or a homolog of the G protein-coupled receptor, which promotes insulin secretion under a high glucose concentration by activation. The invention also relates to cells transformed with an expression vector comprising a polynucleotide encoding and expressing the screening tool. The invention provides a convenient screening method for identifying an agent for treating diabetes, pharmaceutical compositions comprising the agent, and a process for manufacturing the pharmaceutical composition.
REFERENCES:
patent: 3197368 (1965-07-01), Lappe et al.
patent: 6221660 (2001-04-01), Bonini et al.
patent: 6468756 (2002-10-01), Bonini et al.
patent: 7108991 (2006-09-01), Chen et al.
patent: 2003/0017528 (2003-01-01), Chen et al.
patent: 2003/0139590 (2003-07-01), Bonini et al.
patent: 2003/0180813 (2003-09-01), Ohishi et al.
patent: 2004/0067499 (2004-04-01), Haga et al.
patent: 0 608 511 (1994-08-01), None
patent: 1 092 727 (2001-04-01), None
patent: 953899 (1964-04-01), None
patent: WO 87/01257 (1987-03-01), None
patent: WO 00/22131 (2000-04-01), None
patent: WO 00/31258 (2000-06-01), None
patent: WO 00/44382 (2000-08-01), None
patent: WO 00/50562 (2000-08-01), None
patent: WO 01/32864 (2001-05-01), None
patent: WO 01/36473 (2001-05-01), None
patent: WO 01/42288 (2001-06-01), None
patent: WO 01/87929 (2001-11-01), None
patent: WO 02/44362 (2002-06-01), None
patent: WO 02/061087 (2002-08-01), None
patent: WO 02/064789 (2002-08-01), None
Messer W. S. “Vasopressin and Oxytocin” [online], Apr. 3, 2000 [retrieved on Dec. 19, 2006]. Retrieved from the internet: <URL:http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm>.
Communication enclosing a Supplementary Partial European Search Report for EPO Application No. EP 01998193, mailed Mar. 11, 2005 (7 pages).
Attwood, “The Babel of Bioinformatics,” Science, 2000, 290: 471-473.
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, 1990, 247: 1306-1310.
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue,” J. Cell. Biol, 1990, 111:2129-2138.
Kuntz, “Structure-Based Strategies for Drug Design and Discovery;” Science, 1992, 257: 1078-1082.
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Mol. Cell. Biol. 1998, 8:1247-1252.
Metzler et al., “Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28,” Nature Structural Biol., 1997, 4: 527-531.
Miller et al., “Ligand binding to proteins: The binding landscape model,” Protein Science, 1997, 6: 2166-2179.
Rudinger, “1. Characteristics of the amino acids as components of a peptide hormone sequence,” fromPeptide Hormones(ed. J.A. Parsons, M.A., B.M., B.Ch.), University Park Press, Baltimore, Jun. 1976, pp. 1-7.
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era,” Trends in Biotech., 2000, 18(1): 34-39.
Holz et al., “cAMP-dependent Mobilization of Intracellular Ca2+Stores by Activation of Ryanodine Receptors in Pancreatic β-Cells,” J. Biological Chemistry, 274(20): 14147-14156 (1999).
Supplementary Partial European Search Report for EPO Application No. EP 01998193 mailed Jan. 3, 2005.
U.S. Appl. No. 11/657,110, Chen et al.
Fehmann, H-C et al., “Insulinotropic hormone glucagons-like peptide-I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma βTC-1 cells”, Endocrinology, vol. 130, No. 1, pp. 159-166, 1992.
Guo, HH et al., “Protein tolerance to amino acid change”, Proc. Natl. Acad. Sci., vol. 101, No. 25, pp. 9205-9210, Jun. 22, 2004.
Non-Final Office Action dated May 16, 2007 in U.S. Appl. No. 10/511,549.
Amendment Under 37 CFR 1.111 submitted Aug. 16, 2007 in response to Non-Final Office Action dated May 16, 2007 in U.S. Appl. No. 10/511,549.
Declaration of Patent Interference No. 105,561 [U.S. Appl. No. 10/278,437 v. US Patent 7,108,991 and U.S. Appl. No. 11/657,110].
Jeanette Nilsson, et al., “cDNA cloning of human-milk bile salt-stimulated lipase and evidence for its identity to pancreatic carboxylic ester hydrase”, 1990, 192, 543-550.
Applicant's response dated Mar. 9, 2007 filed in U.S. Appl. No. 10/511,549.
Fuhlendorff et al., “Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.”Diabetes47:345-51 (1998).
International Search Report for PCT Application No. PCT/JP03/11548, mailed Oct. 21, 2003.
Kemp et al., “Synergistic effect of dimethyl sulfoxide on glucagon-like peptide 1 (GLP-1)-stimulated insulin secretion and gene transcription in INS-1 cells: characterization and implications.”Biochem. Pharmacol. 64:689-97 (2002).
Office Action mailed Feb. 7, 2007 in U.S. Appl. No. 10/511,549.
U.S. Appl. No. 60/141,448, filed Jun. 29, 1999, Ruoping Chen.
David A. Nielsen, et al., “Control of Insulin Gene Expression in Pancreatic β-Cells and in an Insulin-producing Cell Line, RIN-5F Cells”, The Journal of Biological Chemistry, 1985, 260(25):13585-13589.
Aldo Maldonato, M.D., et al., “Glucose-induced Proinsulin Biosynthesis: Role of Islet Cyclic AMP”, Diabetes, 1977, 26(6):538-545.
Michael Welsh, et al., “Control of Insulin Gene Expression in Pancreatic β-Cells and in an Insulin-producing Cell Line, RIN-5F Cells”, The Journal of Biological Chemistry, 1985, 260(25):13590-13594.
Peter Hammonds, et al., “Regulation and specificity of glucose-stimulated insulin gene expression in human islets of Langerhans”, FEBS Letters, 1987, 223(1):131-137.
Nobuya Inagaki, et al., “c-Jun represses the human insulin promoter activity that depends on multiple cAMP response elements”, Proc. Natl. Acad. Sci USA, 1992, 89:1045-1049.
Nobuya Inagaki, “Regulation of Human Insulin Gene Expression by cAMP”, Molecular Genetics of Diabetes, 1994, 52(10):2528-2532.
“G Protein-Coupled Receptors and Insulin Secretion: 119 and Counting”, Endocrinology, 2007, 148(6):2598-2600.
John Pickup, et al. (Eds.), Textbook of Diabetes, 1997, 2ndEdition, vol. 1.
Stedman's Medical Dictionary, 2006, 28thEdition.
R. Paul Robertson, et al., “G Proteins and Modulation of Insulin Secretion”, Perspectives in Diabetes, 1991, 40:1-6.
Ellenberg and Rifkin's Diabetes Mellitus, 1997, 5thEdition.
Anthony J. Weinhaus, et al., “Role of cAMP in Upregulation of Insulin Secretion During the Adaptation of Islets of Langerhans to Pregnancy”, Diabetes, 1998, 47:1426-1435.
Jonathan Rachman, et al., “Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7-36) Amide in Patients with NIDDM”, Diabetes, 1996, 45:1524-1530.
Takatoshi Soga, et al., “Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor”, Biochemical and Biophysical Research Communications, 2005, 326:744-751.
Wilfred Y. Fujimoto, et al., “Phasic Effects of Glucose, Phospholipase A2, and Lysophospholipids on Insulin Secretion”, Endocrinology, 1987, 120:1750-1757.
Wilfred Y. Fujimoto, et al., “Phasic Effects of Glucose, p-Hydroxymercuribenzoate, and Lysophosphatidylcholine on Insulin Secretion from HIT Cells”, Diabetes, 1989, 38:625-628.
Kamohara Masazumi
Matsumoto Mitsuyuki
Ohishi Takahide
Saito Tetsu
Soga Takatoshi
Astellas Pharma Inc.
Sughrue & Mion, PLLC
Tsang Cecilia
LandOfFree
Method for screening agents for the treatment of diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for screening agents for the treatment of diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for screening agents for the treatment of diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171103